指南与共识腹部泌尿生殖技术与安全CTMRPET

肾细胞癌的分期与基于影像的预后评估:现行指南与实用考量

Staging and imaging-based prognostication in renal cell carcinoma: current guidelines and practical considerations.
指南 / 共识 · Abdom Radiol (NY) · 2026-03-03

本综述阐述肾细胞癌(RCC)基于CT和MRI分期的要点,比较多部主要指南的用法,并探讨整合影像预后标志物(如中央性无强化、强化异质性、扩散指标、影像组学特征)以细化术前风险评估,同时讨论未来方向如光子计数探测器CT、[89Zr]Zr-DFO-girentuximab PET/CT、液体活检整合及标准化报告系统(如肾脏影像报告和数据系统)。

要点

  • 多期CT和MRI是RCC T分期的实用手段,但需注意分期陷阱。
  • 中央性无强化、强化异质性、扩散指标和影像组学特征与肿瘤分级、分期、分子特征及生存相关。
  • 胸部及辅助影像的指征应参照AUA、EAU和NCCN指南。

核心结论

  • 将分期描述与预后表型桥接,旨在标准化报告、更好地指导管理并改善RCC患者的决策。

研究设计与样本

  • 综述,基于美国泌尿外科学会(AUA)、欧洲泌尿外科学会(EAU)和国家综合癌症网络(NCCN)指南,总结多期CT和MRI用于T分期的实用方法、陷阱及胸部与辅助影像指征。

关键影像表现/征象

  • 中央性无强化和强化异质性是影像上可评估的预后生物标志物,与肿瘤分级、分期、分子特征和生存相关。
  • 扩散指标和影像组学特征与RCC结局相关。

临床应用与阅片要点

  • 基于AUA、EAU和NCCN指南概述胸部及辅助影像的指征。
  • 多期CT和MRI可用于RCC的T分期,需注意相关陷阱。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Imaging-based staging is a key component of renal cell carcinoma (RCC) management, yet anatomic labels alone do not fully capture tumor biology. This review highlights key aspects of RCC staging using computed tomography (CT) and magnetic resonance imaging (MRI), compares their use across major guidelines, and explores how integrating imaging-based prognostic markers can refine preoperative risk assessment. We summarize the pragmatic use of multiphase CT and MRI for T-staging, highlight pitfalls, and outline indications for chest and ancillary imaging based on American Urological Association, European Association of Urology, and National Comprehensive Cancer Network guidelines. We also discuss imaging-based prognostic biomarkers, including central non-enhancement and enhancement heterogeneity, diffusion metrics, and radiomic signatures, and we describe how they correlate with outcomes such as tumor grade, stage, molecular features, and survival. In addition, we dive into future directions, focusing on the potential integration of advanced technologies (e.g., photon-counting detector CT, [89Zr] Zr-deferoxamine (DFO)-girentuximab positron emission tomography/CT), integration with liquid biopsy, and development of standardized reporting systems focusing on cancer likelihood and aggressiveness (e.g., Kidney Imaging Reporting and Data System). By bridging staging descriptors with prognostic phenotypes, we aim to standardize reports, better inform management, and improve decision-making for patients with RCC.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Arita Y, Becker A, Leithner D, et al. Staging and imaging-based prognostication in renal cell carcinoma: current guidelines and practical considerations. Abdom Radiol (NY). 2026. PMID: 41774135. doi:10.1007/s00261-026-05432-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。